176 related articles for article (PubMed ID: 33569808)
1. Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib.
Repsold L; Pool R; Karodia M; Tintinger G; Becker P; Joubert AM
Cell Biochem Funct; 2021 Jun; 39(4):562-570. PubMed ID: 33569808
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment.
Repsold L; Pool R; Karodia M; Tintinger G; Joubert AM
Microsc Res Tech; 2022 Jun; 85(6):2222-2233. PubMed ID: 35174933
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
4. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment.
Elkholy MM; Fahmi MW; El-Haggar SM
J Clin Pharm Ther; 2022 Dec; 47(12):2115-2129. PubMed ID: 36053969
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
9. Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and -resistant chronic myeloid leukaemia cells.
Jiang L; Wen C; He Q; Sun Y; Wang J; Lan X; Rohondia S; Dou QP; Shi X; Liu J
Eur J Pharmacol; 2020 Jun; 876():173064. PubMed ID: 32179085
[TBL] [Abstract][Full Text] [Related]
10. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
11. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
12. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
[TBL] [Abstract][Full Text] [Related]
13. In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Marfe G; Di Stefano C
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):58-68. PubMed ID: 19663771
[TBL] [Abstract][Full Text] [Related]
14. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
18. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of variables affecting platelet function in patients with newly diagnosed chronic myeloid leukemia.
Jain A; Arora A; Singh J; Patarwal RN; Prasad P; Chaudhry S; Sharma M; Khunger JM; Gupta DK; Saluja S
Blood Coagul Fibrinolysis; 2020 Dec; 31(8):562-568. PubMed ID: 33181760
[TBL] [Abstract][Full Text] [Related]
20. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
